Current Research Studies

SC-3012, MO41787: A Phase 111b, Multicenter, Open-Label, Single-Arm Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Subcutaneous Emicizumab In Patients from Birth To 12 Months Of Age With Hemophilia A Without Inhibitors


What is the goal of the study?

Study MO41787 will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at 3 mg/kg every 2 weeks (Q2W) for a period of 52weeks in previously untreated patients (PUPs) and minimally treated patients (MTPs) at study enrollment from birth to ?12 months of age with severe hemophilia A (intrinsic FVIII level ?1%) without FVIII inhibitors. After 1 year of treatment, patients will continue to receive emicizumab (1.5 mg/kg once a week [QW], 3 mg/kg Q2W, or 6 mg/kg every 4 weeks [Q4W]) over a 7-year long-term follow-up (LTFU) period, which will evaluate long-term safety of emicizumab and describe the natural history of these patients, including the preservation of joint health over time

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: